Article
Microbiology
T. Nguyen, M. Oualha, C. Briand, M. Bendavid, A. Beranger, S. Benaboud, J-M Treluyer, Y. Zheng, F. Foissac, S. Winter, I Gana, S. Boujaafar, V Lopez, R. Berthaud, Z. Demir, N. Bouazza, D. Hirt
Summary: This study characterized ganciclovir pharmacokinetics in children and optimized dosing schemes for curative or preventive treatment of CMV infections. Dosing recommendations were provided based on body weight and estimated glomerular filtration rate, and individualized therapeutic drug monitoring was suggested for dose refinement.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Antonio C. Arrieta, Michael Neely, J. Christopher Day, Susan R. Rheingold, Paul K. Sue, William J. Muller, Lara A. Danziger-Isakov, Julie Chu, Inci Yildirim, Grace A. McComsey, Haydar A. Frangoul, Tempe K. Chen, Victoria A. Statler, William J. Steinbach, Dwight E. Yin, Kamal Hamed, Mark E. Jones, Christopher Lademacher, Amit Desai, Kelley Micklus, Desiree Leiva Phillips, Laura L. Kovanda, Thomas J. Walsh
Summary: Isavuconazole, administered as the water-soluble prodrug isavuconazonium sulfate, was well tolerated and resulted in exposure in pediatric patients similar to that in adults. Covariate modeling did not show significant impact of age, sex, race, and body mass index on the pharmacokinetic parameters in pediatric patients. The target range of plasma drug exposures was achieved in over 80% and 76% of simulated pediatric patients following intravenous and oral administration, respectively.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Review
Infectious Diseases
Cornelia B. Landersdorfer, Amanda Gwee, Roger L. Nation
Summary: Traditionally, ongoing i.v. antibiotic therapy has been believed to be superior to early i.v. to oral switch for severe infections. However, this belief may not be based on robust data and contemporary clinical studies. This review examines the rationale for an early switch and discusses barriers and perceptions related to this practice.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Pharmacology & Pharmacy
Xiao-bin Lin, Ka Yin Lui, Peng-hao Guo, Xiao-man Liu, Tao Liang, Xiao-guang Hu, Li Tong, Jing-jing Wu, Yan-zhe Xia, Pan Chen, Guo-ping Zhong, Xiao Chen, Chang-jie Cai
Summary: This study established a population pharmacokinetic model of intravenous voriconazole in critically ill patients with liver dysfunction and explored optimal dosing strategies for specific clinical scenarios. The results showed that VRC dosing regimens for patients with different Child-Pugh classes at different MIC values can effectively achieve treatment targets.
Article
Pharmacology & Pharmacy
D. Hirt, M. Oualha, B. Pasquiers, S. Blanot, R. Rubinstazjn, C. Glorion, S. El Messaoudi, D. Drummond, V. Lopez, J. Toubiana, A. Beranger, Sana Boujaafar, Yi Zheng, Carmen Capito, S. Winter, P. L. Leger, R. Berthaud, Ines Gana, F. Foissac, J. M. Treluyer, N. Bouazza, S. Benaboud
Summary: This study aimed to characterize the pharmacokinetics of intravenous and oral ciprofloxacin in children and optimize dosing schemes for treating bacterial infections. The recommended doses for ciprofloxacin based on body weight and estimated glomerular filtration rate were provided, with adjustments necessary for different bacterial strains. Prospective confirmation and therapeutic drug monitoring are suggested for individual refinement of dosing.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xin Li, Chenjing Wang, Ping Shi, Yanping Liu, Ye Tao, Pingping Lin, Ting Li, Haixun Hu, Feifei Sun, Shuqin Liu, Yao Fu, Yu Cao
Summary: The study evaluated the pharmacokinetic equivalency of a test formulation and reference formulation of Voriconazole. The results showed that the pharmacokinetic characteristics of the test and reference formulations met the criteria of bioequivalence for both the 4 mg/kg and 6 mg/kg dose groups.
BMC PHARMACOLOGY & TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
Junichi Yamamoto, Kaori Ikeda, Armel Stockis
Summary: This study characterized the bioavailability, safety, and tolerability of brivaracetam in healthy Japanese participants. The results showed that the AUC ratios of intravenous and oral administration were within the bioequivalence limits, but the C-max exceeded the limits. Therefore, no dose adjustment is needed when switching from oral to intravenous dosing, but further investigations are required to assess the safety and tolerability in patients with epilepsy.
Article
Immunology
Fleur M. Keij, Stef Schouwenburg, Rene F. Kornelisse, Tim Preijers, Fatima Mir, Pieter Degraeuwe, Leo M. Stolk, Arianne van Driel, Sandra Kenter, Jacqueline van der Sluijs, Jojanneke Heidema, Paul C. P. den Butter, Irwin K. M. Reiss, Karel Allegaert, Gerdien A. Tramper-Stranders, Birgit C. P. Koch, Robert B. Flint
Summary: This study describes the metabolism of oral and intravenous amoxicillin in neonates and provides dosage recommendations for different age groups. Oral amoxicillin therapy is an effective, cost-effective, and convenient alternative treatment for neonates.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Chemistry, Medicinal
Li Zhang, Xin-Mei Yang, Jing Chen, Lei Hu, Fan Yang, Yue Zhou, Bei-Bei Zhao, Wei Zhao, Xiao-Fan Zhu
Summary: The pharmacokinetics and safety of the oral AS(4)S(4) formula were evaluated for the first time in pediatric APL patients. The dosing regimen of 60 mg/kg/d TID resulted in a higher steady-state through concentration in children than in adults, showing it to be safe and effective.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Infectious Diseases
Mikio Ishii, Yuji Orito, Mari Shiomi, Rebecca E. Wrishko, Hiroyuki Yoshitsugu
Summary: The pharmacokinetics of daptomycin were evaluated in Japanese pediatric patients with complicated skin and soft tissue infections or bacteremia. The age-specific, weight-based dosing regimens were found to be appropriate in Japanese pediatric patients based on PK comparison with Japanese adult patients.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2023)
Article
Medicine, General & Internal
Youran Cai, Shimei Song, Yiying Chen, Xuyang Xu, Wenjin Zou
Summary: This study retrospectively analyzed the efficacy and safety of oral voriconazole as a primary treatment for fungal keratitis. The results indicated that oral voriconazole monotherapy was successful in patients with fungal keratitis. Patients with ulcers larger than 5 x 5 mm(2) and hypopyon were less likely to respond to this treatment.
FRONTIERS IN MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Phanit Songvut, Nuchanart Rangkadilok, Nanthanit Pholphana, Tawit Suriyo, Duangchit Panomvana, Porranee Puranajoti, Jaratluck Akanimanee, Jutamaad Satayavivad
Summary: The study investigates the safety profiles and clinical pharmacokinetics of Andrographis paniculata aqueous extract in treating COVID-19. The results show a dose-dependent effect between the two different doses, with a twofold increase in the dose leading to twofold higher plasma concentrations of the active compounds. Safety evaluation indicates mild and reversible adverse events, with consideration needed for patients with hepatic or kidney dysfunction.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Taotao Wang, Miao Yan, Dan Tang, Yuzhu Dong, Li Zhu, Qian Du, Dan Sun, Jianfeng Xing, Yalin Dong
Summary: The study retrospectively analyzed the pharmacokinetics of voriconazole in cirrhotic patients and recommended reducing maintenance doses for these patients, based on the optimized regimens. The research suggests that cirrhotic patients should receive lower maintenance doses of voriconazole.
Article
Microbiology
A. Young J. Park, Dat Q. Tran, Justin B. Schaal, Mengxi Wang, Michael E. Selsted, Paul M. Beringer
Summary: This study characterized the preclinical pharmacokinetics and safety of intravenous RTD-1. The results showed extensive tissue distribution and excellent safety profile for RTD-1, supporting its clinical investigation for the treatment of COVID-19 or other pulmonary inflammatory diseases.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Medical Laboratory Technology
Omar Elkayal, Isabel Spriet, Anne Uyttebroeck, Anca Colita, Pieter Annaert, Karel Allegaert, Anne Smits, Ruth Van Daele, Erwin Dreesen
Summary: The study developed a popPK model for posaconazole oral suspension in pediatric patients, showing significant PK variability. The probability of target attainment for prophylactic treatment was below 85%, indicating the need for therapeutic drug monitoring. Large-scale comparative studies are necessary to characterize PK variability between different posaconazole formulations in this patient population.
THERAPEUTIC DRUG MONITORING
(2021)